Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients | Zendy

Mark Oette | Zendy; Michael Kurowski | Zendy; Torsten Feldt | Zendy; Arne Kroidl | Zendy; Abdurrahman Sagir | Zendy; C Vogt | Zendy; M Wettstein | Zendy; Dieter Häussinger | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients

Author(s) -

Mark Oette,

Michael Kurowski,

Torsten Feldt,

Arne Kroidl,

Abdurrahman Sagir,

C Vogt,

M Wettstein,

Dieter Häussinger

Publication year - 2005

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dki234

Subject(s) - cmin , cmax , medicine , nevirapine , rosiglitazone , lopinavir , efavirenz , ritonavir , pharmacology , abacavir , bioavailability , pharmacokinetics , confidence interval , gastroenterology , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy , insulin , immunology

The insulin-sensitizer rosiglitazone is under investigation for therapy of HIV-associated lipodystrophy syndrome (LDS). Little is known about pharmacological interactions with antiretroviral (ARV) drugs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research